Discussion on research and development models in innovative Chinese materia medica

Chinese Traditional and Herbal Drugs

Volumn 42, Issue 7, 2011, Pages 1255-1260

  Chen, Xiu Ping ^a,b   Pei, Li Xia ^c   Wang, Yi Tao ^a,b  

^a State Key Laboratory of Quality Research in Chinese Medicine   (Macao)

^b University of Macau   (Macao)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Artemisinin; Compound Danshen Dripping Pills; Drug discovery model; Innovative Chinese materia medica; Modernization of Chinese materia medica

Indexed keywords

CHINESE DRUG; CHINESE MATERIA MEDICA; MATERIA MEDICA; UNCLASSIFIED DRUG;

ARTICLE; CHINESE MEDICINE; DRUG DEVELOPMENT; NOMENCLATURE; PHILOSOPHY;

EID: 84872524546     PISSN: 02532670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. 2010, 25(5): 321-326.
2. Liu C X, Xiao P G, Peng Y, et al. Challenges in research and development of traditional Chinese medicines [J]. Chin Herb Med, 2009, 1(1): 1-28.
3. Chen K K, Schmidt C F. The action of ephedrine, the active principle of the Chinese drug Ma huang [J]. J Pharmacol Exp Ther, 1924, 24(5): 339-357.
4. Kuttan G, Kumar K B, Guruvayoorappan C, et al. Antitumor, anti-invasion, and antimetastatic effects of curcumin [J]. Adv Exp Med Biol, 2007, 595: 173-184.
5. Zhang C L, Wu L J, Tashiro S, et al. Oridonin induced A375-S2 cell apoptosis via bax-regulated caspase pathway activation, dependent on the cytochrome c/caspase-9 apoptosome [J]. J Asian Nat Prod Res, 2004, 6(2): 127-138.
6. Ikezoe T, Yang Y, Bandobashi K, et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways [J]. Mol Cancer Ther, 2005, 4(4): 578-586.
7. Zhang Y, Wu Y, Tashiro S, et al. Involvement of PKC signal pathways in oridonin-induced autophagy in HeLa cells: a protective mechanism against apoptosis [J]. Biochem Biophys Res Commun, 2009, 378(2): 273-278.
8. Ng L T, Chiang L C, Lin Y T, et al. Antiproliferative and apoptotic effects of tetrandrine on different human hepatoma cell lines [J]. Am J Chin Med, 2006, 34(1): 125-135.
9. Wenzel U, Herzog A, Kuntz S, et al. Protein expression profiling identifies molecular targets of quercetin as a major dietary flavonoid in human colon cancer cells [J]. Proteomics, 2004, 4(7): 2160-2174.
10. Huang Y T, Hwang J J, Lee P P, et al. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor [J]. Br J Pharmacol, 1999, 128(5): 999-1010.
11. Shoemaker R H. The NCI60 human tumour cell line anticancer drug screen [J]. Nat Rev Cancer, 2006, 6(10): 813-823.
12. 2005, 36(11): 1734-1736.
13. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses [J]. J Food Sci, 2008, 73(1): 14-19.
14. 2010, 33(6): 452-456.
15. 2010, 41(6): 945-949.
16. Suzuki J, Isobe M, Morishita R, et al. Tea polyphenols regulate key mediators on inflammatory cardiovascular diseases [J]. Mediators Inflamm, doi: 10.1155/2009/494928, 2009.
17. Lambert J D, Elias R J. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention [J]. Arch Biochem Biophys, 2010, 501(1): 65-72.
18. Li Q S, Zou L L, Fu T, et al. Excretion of four catechins in tea polyphenols in rats [J]. Chin Herb Med, 2009, 1(1): 59-65.
19. Wang C Y, Li Q S, Han G Z, et al. A specific and sensitive LC-MS/MS method for simultaneous determination of four major active catechins of tea polyphenols in rat plasma and its application to pharmacokinetic study [J]. Chin Herb Med, 2010, 2(4): 289-296.
20. Yang Y F, Feng J Q, Xu H Y, et al. Influence of different extraction and purification methods on astragalus polysaccharides and pharmacological evaluation [J]. Chin Herb Med, 2010, 2(1): 54-61.
21. 2010, 41(1): 1-5.
22. Lam W, Bussom S, Guan F, et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity [J]. Sci Transl Med, 2010, 2(45): 45-59.
23. Eng C. Are herbal medicines ripe for the cancer clinic? [J]. Sci Transl Med, 2010, 2(45): 45.
24. Hedigan K. Cancer: Herbal medicine reduces chemotherapy toxicity [J]. Nat Rev Drug Discov, 2010, 9(10): 765.
25. Weng C J, Yen G C. The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis [J]. Clin Exp Metast, 2010, 27(5): 361-369.
26. Lin Z B, Zhang H N. Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms [J]. Acta Pharmacol Sin, 2004, 25(11): 1387-1395.
27. Taixiang W, Munro A J, Guanjian L. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients [J]. Cochrane Database Syst Rev, 2005, 25(1): CD004540.
28. Li J, Bao Y, Lam W, et al. Immunoregulatory and anti-tumor effects of polysaccharopeptide and Astragalus polysaccharides on tumor-bearing mice [J]. Immunopharmacol Immunotoxicol, 2008, 30(4): 771-782.
29. 2011, 34(1): 1-7.
30. 2002, 4(6): 31-38.
31. 2001, 21(4): 295-299.
32. DiPaola R S, Zhang H, Lambert G H, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer [J]. N Engl J Med, 1998, 339(12): 785-791.
33. Small E J, Frohlich M W, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer [J]. J Clin Oncol, 2000, 18(21): 3595-3603.
34. Walsh P C. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer [J]. J Urol, 2005, 173(6): 1966-1967.
35. Shabbir M, Love J, Montgomery B. Phase I trial of PC-Spes2 in advanced hormone refractory prostate cancer [J]. Oncol Rep, 2008, 19(3): 831-835.
36. Barabasi A L, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease [J]. Nat Rev Genet, 2011, 12(1): 56-68.
37. Schadt E E, Friend S H, Shaywitz D A. A network view of disease and compound screening [J]. Nat Rev Drug Discov, 2009, 8(4): 286-295.